Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Thursday

Avalo Therapeutics (NASDAQ:AVTX) will likely be announcing its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect Avalo Therapeutics to post earnings of ($1.54) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 26, 2026 at 9:30 AM ET.

Avalo Therapeutics Stock Up 1.1%

Shares of AVTX stock opened at $17.10 on Thursday. The company has a market capitalization of $316.52 million, a P/E ratio of -3.19 and a beta of 0.84. Avalo Therapeutics has a 12-month low of $3.39 and a 12-month high of $20.72. The firm has a 50-day moving average price of $15.95 and a 200 day moving average price of $15.43.

Analyst Ratings Changes

A number of research analysts have recently issued reports on AVTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. Mizuho upgraded Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Guggenheim initiated coverage on Avalo Therapeutics in a research report on Monday, February 2nd. They issued a “buy” rating and a $50.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Avalo Therapeutics in a research note on Thursday, January 15th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $33.00.

Institutional Trading of Avalo Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of AVTX. XTX Topco Ltd increased its position in shares of Avalo Therapeutics by 190.0% in the 4th quarter. XTX Topco Ltd now owns 40,458 shares of the company’s stock valued at $735,000 after buying an additional 26,508 shares in the last quarter. Squadron Capital Management LLC bought a new position in Avalo Therapeutics during the fourth quarter worth about $2,361,000. SummitTX Capital L.P. acquired a new position in Avalo Therapeutics in the fourth quarter valued at about $3,557,000. Millennium Management LLC grew its stake in Avalo Therapeutics by 380.2% in the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock valued at $11,985,000 after acquiring an additional 522,548 shares during the period. Finally, Caligan Partners LP increased its holdings in shares of Avalo Therapeutics by 5.8% in the fourth quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock worth $16,009,000 after acquiring an additional 48,200 shares in the last quarter. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.